A nested case control study of Plasma ICAM-1, E-selectin and TNF receptor 2 levels, and incident primary open- angle glaucoma

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 1797-1804

  Kang, Jae H ^a   Wiggs, Janey L ^b   Pasquale, Louis R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; QUESTIONNAIRE; RISK;

ADULT; AGED; CASE-CONTROL STUDIES; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 84875423021     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11191     Document Type: Article

References (77)

1. Pasquale LR, Willett WC, Rosner BA, Kang JH. Anthropometric measures and their relation to incident primary open-angle glaucoma. Ophthalmology. 2010;117:1521-1529.
2. Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR, Jansonius NM. Lifestyle and risk of developing open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2011;129: 767-772.
3. Ronnemaa T, Pulkki K, Kaprio J. Serum soluble tumor necrosis factor-alpha receptor 2 is elevated in obesity but is not related to insulin sensitivity: a study in identical twins discordant for obesity. J Clin Endocrinol Metab. 2000;85:2728-2732.
4. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997;46:451-455.
5. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factoralpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.
6. Saini A, Al-Shanti N, Stewart CE. Waste management-cytokines, growth factors and cachexia. Cytokine Growth Factor Rev. 2006;17:475-486.
7. Song Y, Manson JE, Tinker L, et al. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. Diabetes. 2007;56:1898-1904.
8. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
9. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med. 1999;107:85-97.
10. Su WW, Cheng ST, Ho WJ, Tsay PK, Wu SC, Chang SH. Glaucoma is associated with peripheral vascular endothelial dysfunction. Ophthalmology. 2008;115:1173-1178. e1171.
11. Henry E, Newby DE, Webb DJ, O'Brien C. Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci. 1999;40:1710-1714.
12. Barton J, Bain C, Hennekens CH, et al. Characteristics of respondents and non-respondents to a mailed questionnaire. Am J Public Health. 1980;70:823-825.
13. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded selfadministered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol. 1992;135: 1114-1126.
14. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-329.
15. De Groote D, Grau GE, Dehart I, Franchimont P. Stabilisation of functional tumor necrosis factor-alpha by its soluble TNF receptors. Eur Cytokine Netw. 1993;4:359-362.
16. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr. 2004;79:606-612.
17. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7:231-240.
18. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol. 1995;54:1-8.
19. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060-3067.
20. Fernandez-Real JM, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47:1757-1762.
21. Fernandez-Real JM, Gutierrez C, Ricart W, Castineira MJ, Vendrell J, Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis. 1999; 146:321-327.
22. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92:1479-1486.
23. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693-700.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
25. Pasquale LR, Kang JH. Female reproductive factors and primary open-angle glaucoma in the Nurses' Health Study. Eye (Lond). 2011;25:633-641.
26. Hulsman CA, Westendorp IC, Ramrattan RS, et al. Is openangle glaucoma associated with early menopause? The Rotterdam Study. Am J Epidemiol. 2001;154:138-144.
27. Affinito P, Di Spiezio Sardo A, Di Carlo C, et al. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause. 2003;10:482-487.
28. Altintas O, Caglar Y, Yuksel N, Demirci A, Karabas L. The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica. 2004;218:120-129.
29. Sator MO, Joura EA, Frigo P, et al. Hormone replacement therapy and intraocular pressure. Maturitas. 1997;28:55-58.
30. Sorrentino C, Affinito P, Mattace Raso F, et al. Effect of hormone replacement therapy on postmenopausal ocular function [in Italian]. Minerva Ginecol. 1998;50:19-24.
31. Uncu G, Avci R, Uncu Y, Kaymaz C, Develioglu O. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol. 2006;22:501-505.
32. Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary openangle glaucoma: a prospective study. J Glaucoma. 2007;16: 598-605.
33. Akar ME, Taskin O, Yucel I, Akar Y. The effect of the menstrual cycle on optic nerve head analysis in healthy women. Acta Ophthalmol Scand. 2004;82:741-745.
34. Yucel I, Akar M, Durukan A, et al. The effect of the menstrual cycle on the optic nerve head analysis of migrainous women. Current Eye Res. 2005;30:163-169.
35. Akar Y, Yucel I, Akar ME, Taskin O, Ozer HO. Menstrual cycledependent changes in visual field analysis of healthy women. Ophthalmologica. 2005;219:30-35.
36. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4:65-69.
37. Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20:8693-8700.
38. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787-1794.
39. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32:42-50.
40. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinase and tumor necrosis factor in glaucomatous optic nerve head. Arch Ophthalmol. 2000;118:666-673.
41. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci. 2006;26:12633-12641.
42. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci. 2002;22: RC216.
43. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev. 1999;10:119-130.
44. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-65.
45. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res. 2008;173:409-421.
46. Fingert JH, Robin AL, Stone JL, et al. Copy number variations on chromosome 12q14 in patients with normal tension glaucoma. Hum Mol Genet. 2011;20:2482-2494.
47. Boss CJ, Lip GYH. Is hypertension an inflammatory process? Curr Pharm Des. 2006;12:1623-1635.
48. Drance SM, Sweeney VP, Morgan RW, Feldman F. Studies of factors involved in the production of low tension glaucoma. Arch Ophthalmol. 1973;89:457-465.
49. Grunwald JE, Piltz J, Harpiprasad SM, Dupont J, Maguire MG. Optic nerve blood flow in glaucoma: effect of systemic hypertension. Am J Ophthalmol. 1999;127:516-522.
50. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest. 1997;100:2777-2782.
51. Finck BN, Kelley KW, Dantzer R, Johnson RW. In vivo and in vitro evidence for the involvement of tumor necrosis factoralpha in the induction of leptin by lipopolysaccharide. Endocrinology. 1998;139:2278-2283.
52. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003;11:525-531.
53. Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normalweight and obese women: effect of adiposity and diabetes. Eur J Endocrinol. 2002;146:325-331.
54. Signore AP, Zhang F, Weng Z, Gao Y, Chen J. Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J Neurochem. 2008;106:1977-1990.
55. Russo VC, Metaxas S, Kobayashi K, Harris M, Werther GA. Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology. 2004;145:4103-4112.
56. Guo Z, Jiang H, Xu X, Duan W, Mattson MP. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J Biol Chem. 2008; 283:1754-1763.
57. Chu NF, Shen MH, Wu DM, Shieh SM. Plasma TNF-R1 and insulin concentrations in relation to leptin levels among normal and overweight children. Clin Biochem. 2002;35:287-292.
58. Dixon D, Goldberg R, Schneiderman N, Delamater A. Gender differences in TNF-alpha levels among obese vs nonobese Latino children. Eur J Clin Nutr. 2004;58:696-699.
59. Pfeiffer A, Janott J, Mohlig M, et al. Circulating tumor necrosis factor alpha is elevated in male but not in female patients with type II diabetes mellitus. Horm Metab Res. 1997;29:111-114.
60. Leinonen V, Menon LG, Carroll RS, et al. Cerebrospinal fluid biomarkers in idiopathic normal pressure hydrocephalus. Int J Alzheimers Dis. 2011;2011:312526.
61. Wostyn P, Audenaert K, De Deyn PP. High occurrence rate of glaucoma among patients with normal pressure hydrocephalus. J Glaucoma. 2010;19:225-226.
62. Chang TC, Singh K. Glaucomatous disease in patients with normal pressure hydrocephalus. J Glaucoma. 2009;18:243-246.
63. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7:e40065.
64. Huang P, Qi Y, Xu YS, et al. Serum cytokine alteration is associated with optic neuropathy in human primary open angle glaucoma. J Glaucoma. 2010;19:324-330.
65. Ghanem AA, Arafa LF, Elewa AM. Tumor necrosis factor-alpha and interleukin-6 levels in patients with primary open-angle glaucoma. Clin Exp Ophthalmol. 2011;2:118.
66. Balaiya S, Edwards J, Tillis T, Khetpal V, Chalam KV. Tumor necrosis factor-alpha (TNF-alpha) levels in aqueous humor of primary open angle glaucoma. Clin Ophthalmol. 2011;5:553-556.
67. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factoralpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci. 2010;51:903-906.
68. Lin HJ, Tsai FJ, Chen WC, Shi YR, Hsu Y, Tsai SW. Association of tumour necrosis factor alpha-308 gene polymorphism with primary open-angle glaucoma in Chinese. Eye. 2003;17:31-34.
69. Funayama T, Ishikawa K, Ohtake Y, et al. Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma. Invest Ophthalmol Vis Sci. 2004;45:4359-4367.
70. Mossbock G, Weger M, Moray M, et al. TNF-alpha promoter polymorphisms and primary open-angle glaucoma. Eye. 2006; 20:1040-1043.
71. Razeghinejad MR, Rahat F, Kamali-Sarvestani E. Association of TNFA-308 G/A and TNFRI{thorn}36 A/G gene polymorphisms with glaucoma. Ophthalmic Res. 2009;42:118-124.
72. Fan BJ, Liu K, Wang DY, et al. Association of polymorphisms of tumor necrosis factor and tumor protein p53 with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2010;51: 4110-4116.
73. Yu QQ, Yao YA. Detailed meta-analysis shows no association between TNF-alpha-308G/A polymorphism and different forms of glaucoma. Ophthalmic Res. 2012;47:47-51.
74. Wang CY, Shen YC, Wei LC, et al. Polymorphism in the TNFalpha(863) locus associated with reduced risk of primary open angle glaucoma. Mol Vis. 2012;18:779-785.
75. Kaiser HJ, Flammer J, Wenk M, Luscher T. Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol. 1995; 233:484-488.
76. Emre M, Orgul S, Haufschild T, Shaw SG, Flammer J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br J Ophthalmol. 2005;89:60-63.
77. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.